Regeneron

Regeneron, Alnylam spell out a research alliance that could run beyond a decade, with billions built in for success
Regeneron, Alnylam spell out a research alliance that could run beyond a decade, with billions built in for success
Endpoints
Regeneron
Alnylam
R&D
Flag link:
Alnylam Gets $800M From Regeneron to Bring RNAi to Eye, Brain Diseases
Alnylam Gets $800M From Regeneron to Bring RNAi to Eye, Brain Diseases
Xconomy
Alnylam
Regeneron
RNAi
eye health
brain diseases
Flag link:
FDA approves Dupixent for atopic dermatitis in adolescents
FDA approves Dupixent for atopic dermatitis in adolescents
BioCentury
Dupixent
Regeneron
Sanofi
FDA
atopic dermatitis
Flag link:
Sanofi/Regeneron’s Dupixent shows more promise in nasal polyps
Sanofi/Regeneron’s Dupixent shows more promise in nasal polyps
Pharmaforum
Sanofi
Regeneron
Dupixent
clinical trials
nasal polyps
Flag link:
Regeneron touts one-year diabetic retinopathy data for Eylea
Regeneron touts one-year diabetic retinopathy data for Eylea
Drug Delivery Business News
Regeneron
Eylea
proliferative diabetic retinopathy
Flag link:
Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen
Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen
Biopharma Dive
Regeneron
Sanofi
Amgen
Praluent
Repatha
drug pricing
PCSK9 inhibitors
Flag link:
Forget Bristol-Myers: Regeneron takes on Merck for the heavyweight title in non-small cell lung cancer
Forget Bristol-Myers: Regeneron takes on Merck for the heavyweight title in non-small cell lung cancer
Endpoints
Regeneron
Merck
Bristol-Myers Squibb
PD-1/L1 therapy
Libtayo
Keytruda
Opdivo
non-small cell lung cancer
Flag link:
Successful launch bolsters Libtayo's place as cornerstone therapy for Regeneron
Successful launch bolsters Libtayo's place as cornerstone therapy for Regeneron
Biopharma Dive
Regeneron
Libtayo
earnings
CSCC
drug launches
Flag link:
Report: five companies would take brunt of Trump Part B proposal
Report: five companies would take brunt of Trump Part B proposal
BioCentury
Donald Trump
Medicare Part B
Amgen
Regeneron
Bristol-Myers Squibb
Genentech
Roche
Flag link:
Is the Smoldering NASH Market Ready to Burst Into Flames?
Is the Smoldering NASH Market Ready to Burst Into Flames?
BioSpace
NASH
Allergan
Regeneron
Alnylam
AstraZeneca
Merck
Takeda
Gilead Sciences
Bristol-Myers Squibb
Intercept Pharmaceuticals
Flag link:
Day One of JPM Brings Excitement and Promise for a New Year in Biotech and Pharma
Day One of JPM Brings Excitement and Promise for a New Year in Biotech and Pharma
BioSpace
JPMHC 2019
M&A
Eli Lilly
Loxo Oncology
SAGE Therapeutics
Sanofi
Regeneron
Bristol-Myers Squibb
Celgene
Novartis
Gilead Sciences
Flag link:
Sanofi pays Regeneron $462M to exit immuno-oncology R&D pact
Sanofi pays Regeneron $462M to exit immuno-oncology R&D pact
Fierce Biotech
Sanofi
Regeneron
immuno-oncology
Flag link:
7 drugs that raised eyebrows in Q3
7 drugs that raised eyebrows in Q3
Biopharma Dive
Sanofi
Dupixent
Roche
Herceptin
AbbVie
Humira
Regeneron
Repatha
Clovis Oncology
Rubraca
GSK
Shingrix
Eli Lilly
Trulicity
Flag link:
Going gangbusters in atopic dermatitis, the FDA hands Sanofi and Regeneron a fresh coup for their mega-blockbuster star Dupixent
Going gangbusters in atopic dermatitis, the FDA hands Sanofi and Regeneron a fresh coup for their mega-blockbuster star Dupixent
Endpoints
Sanofi
Regeneron
Dupixent
atopic dermatitis
Flag link:
Early November Brings More Quarterly Reports
Early November Brings More Quarterly Reports
BioSpace
earnings
Akcea
Mylan
Eli Lilly
Regeneron
Flag link:
Roche expands its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab
Roche expands its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab
Endpoints
Roche
Genentech
Regeneron
Novartis
Eylea
faricimab
wet-AMD
Flag link:
Regeneron and Roche Duke it Out in the Diabetic Retinopathy Market
Regeneron and Roche Duke it Out in the Diabetic Retinopathy Market
BioSpace
Regeneron
Eylea
diabetic retinopathy
Roche
Lucentis
Flag link:
FDA kicks Regeneron’s latest Eylea application to the curb, but they’re not sweating it
FDA kicks Regeneron’s latest Eylea application to the curb, but they’re not sweating it
Endpoints
Regeneron
FDA
Eylea
complete response letter
Flag link:
Regeneron, Sanofi talks up potential blockbuster franchise as Dupixent sweeps in rhinosinusitis PhIII
Regeneron, Sanofi talks up potential blockbuster franchise as Dupixent sweeps in rhinosinusitis PhIII
Endpoints
Regeneron
Sanofi
Dupixent
nasal polyps
rhinosinusitis
Flag link:
7 drugmakers to watch during Q3 earnings
7 drugmakers to watch during Q3 earnings
Biopharma Dive
earnings
Novartis
Gilead Sciences
Amgen
Pfizer
GSK
AbbVie
Regeneron
Flag link:

Pages